Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti‐HIV‐1 Agents | Zendy

Zhang Lingzi | Zendy; Guo Jian | Zendy; Liu Xin | Zendy; Liu Huiqing | Zendy; De Clercq Erik | Zendy; Pannecouque Christophe | Zendy; Liu Xinyong | Zendy

Premium

Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti‐HIV‐1 Agents

Author(s) -

Zhang Lingzi,

Guo Jian,

Liu Xin,

Liu Huiqing,

De Clercq Erik,

Pannecouque Christophe,

Liu Xinyong

Publication year - 2015

Publication title -

chemical biology and drug design

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.59

H-Index - 77

eISSN - 1747-0285

pISSN - 1747-0277

DOI - 10.1111/cbdd.12497

Subject(s) - chemistry , lead compound , ether , human immunodeficiency virus (hiv) , enzyme , combinatorial chemistry , active compound , stereochemistry , diphenyl ether , rational design , reverse transcriptase , ec50 , in vitro , biochemistry , virology , organic chemistry , biology , rna , genetics , gene

A series of benzoyl diarylamine/ether derivatives were designed, synthesized, and evaluated for their activity against human immunodeficiency virus ( HIV ) in MT ‐4 cells. Three compounds ( 3b , 5a, and 6a1 ) exhibited moderate activities against wild‐type (wt) HIV ‐1 with EC 50 values ranging from 11 to 56 μ m . Among them, compound 5a was the most potent inhibitor with a novel chemical skeleton, affording a new lead compound for further molecular optimization. An enzyme assay was also implemented to confirm the binding target of the active compounds represented by 6a1 . Molecular simulation studies on compound 5a , 6a1, and 7a4 were carried out to understand their binding mode with wt HIV ‐1 reverse transcriptase ( RT ) and provided useful information for further rational design of NNRTI s.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research